6533b857fe1ef96bd12b46a6

RESEARCH PRODUCT

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

Vincenzo SerrettaDarvinio MelloniAnna MartoranaA CataneseR. LiottaF AragonaG. DaricelloRosalinda Allegro

subject

MaleRiskCancer Researchmedicine.medical_specialtyTime FactorsProstate biopsymedicine.drug_classUrologyAntibioticsUrologyProstatitisUnnecessary Proceduresurologic and male genital diseasesSettore MED/24 - UrologiaDiagnosis DifferentialProstate cancerCiprofloxacinBiopsyCarcinomaHumansMedicineUltrasonography InterventionalAgedAged 80 and overPalpationmedicine.diagnostic_testbusiness.industryPatient SelectionBiopsy NeedleProstateProstatic NeoplasmsCancerHistologyOrgan SizeMiddle AgedProstate-Specific Antigenmedicine.diseaseAnti-Bacterial AgentsProstatitisOncologybusinessprostate-specific antigen (PSA) prostatitis prostate carcinomaFollow-Up Studies

description

Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P=0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.

yearjournalcountryeditionlanguage
2007-07-17
10.1038/sj.pcan.4500996http://hdl.handle.net/10447/47165